share_log
Benzinga ·  May 7 07:27
Entrada Therapeutics Expects Cash Runway Through The Second Quarter Of 2026 With $327M In Cash, Cash Equivalents And Marketable Securities As Of March 31, 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment